Free tool
FAERS Monitor: Ruby-Fill
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202153 or its brand name (Ruby-Fill, Rubidium Chloride Rb-82). Reports on generic versions are filed under their own applications.
Reports
15
Serious
0
0% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective6
- underdose6
- product preparation error5
- device use error2
- incorrect dose administered by device2
- back pain1
- decreased appetite1
- headache1
- lip swelling1
- pain1
- paraesthesia1
- product delivery mechanism issue1
- renal pain1
- sleep disorder1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,144 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product preparation errorSignal | 5 | 341.3 | 166.8 | 1,374 |
| product delivery mechanism issue | 1 | 260.8 | 39.3 | 64 |
| renal pain | 1 | 132.3 | 19.9 | 32 |
| underdoseSignal | 6 | 115.3 | 62.0 | 572 |
| incorrect dose administered by device | 2 | 107.0 | 29.4 | 118 |
| device use error | 2 | 80.7 | 22.2 | 88 |
| lip swelling | 1 | 42.1 | 6.3 | 10 |
| sleep disorder | 1 | 19.9 | 3.0 | 4 |
| paraesthesia | 1 | 8.9 | 1.3 | 1 |
| drug ineffectiveSignal | 6 | 6.4 | 3.4 | 24 |
| decreased appetite | 1 | 6.0 | 0.9 | 1 |
| back pain | 1 | 6.0 | 0.9 | 1 |
| pain | 1 | 2.3 | 0.3 | 0 |
| headache | 1 | 2.2 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.